A new treatment for Parkinson’s disease developed from decades of research at the University of Virginia has received ...
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
A new drug for Parkinson’s disease that seem to cause fewer serious side effects than some existing treatments has been ...
A new daily pill could help people with Parkinson’s disease live more of their life without symptoms, a trial has found.
The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors ...
Major Parkinson’s breakthrough as new pill offers hope of treating symptoms and has fewer side-effects - Trial found patients on solengepras had 37 minutes less ‘off’ time each day when dopamine drugs ...
AbbVie’s JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s ...
Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...
Experts speaking to the Mail have revealed we are on the cusp of a revolution in Parkinson's treatment, with a new generation of drugs designed not simply to manage symptoms but to tackle the disease ...
AbbVie recently received U.S. FDA approval for JUVMO (tavapadon) tablets, the first and only selective D1/D5 receptor agonist ...
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results